EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Analysis of the Recovery of Immune Status in the Patients With Paroxysmal Nocturnal Hemoglobinuria After Treatment With C5 Complement Inhibitor

Hui Liu iD, Mengting Che iD, Liyan Li iD, Honglei Wang, Chaomeng Wang, Junshu Wu, Yingying Chen iD, Zhaoyun Liu iD, Lijuan Li, Rong Fu iD

Journal of Clinical Laboratory Analysis · 2026-06 · 40 (12)

DOI: 10.1002/jcla.70211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, online erschienen am 29.04.2026. Verfasst von Hui Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal, Complement C5, Complement Inactivating Agents. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, the Tianjin Municipal Natural Science Foundation, the Tianjin Science and Technology Planning Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Currently, C5 complement inhibitors serve as the first‐line therapy for classic paroxysmal nocturnal hemoglobinuria (PNH), effectively controlling hemolysis and enhancing patients' quality of life. However, the impact of this treatment on patients' immune status remains unclear.

Methods

A retrospective analysis was conducted on 27 PNH patients treated with C5 complement inhibitors, focusing on the dynamic changes and recovery of key immune cell subsets, including T lymphocytes, B lymphocytes, natural killer (NK) cells, and dendritic cells (DCs).

Results

Among the 27 patients, 70.3% (19/27) achieved transfusion independence. Treatment responses were categorized as follows: complete response (7.4%, 2/27), major response (3.7%, 1/27), good response (25.9%, 7/27), partial response (22.2%, 6/27), minor response (29.6%, 8/27), and non‐response (11.1%, 3/27). Before treatment, the proportion of CD4 + T lymphocytes was significantly lower in PNH patients than in normal controls [(38.96 ± 8.270)% vs. (48.57 ± 5.760)%, p < 0.001], and it gradually recovered toward normal levels at 12 months [(42.48 ± 5.623)%] and 24 months [(43.71 ± 6.204)%] post‐treatment. In contrast, the percentage of CD8 + T lymphocytes was markedly elevated in pre‐treatment patients compared with controls [(49.38 ± 7.259)% vs. (41.75 ± 4.744)%, p < 0.01], and it returned to near‐normal levels at 12 months [(42.97 ± 7.074)%]. The proportion of B lymphocytes was significantly reduced in pre‐treatment PNH patients [(6.535 ± 1.854)% vs. (12.70 ± 2.256)% in controls, p < 0.001] and partially recovered at 6, 12, and 24 months post‐treatment [(8.266 ± 1.756)%, (8.626 ± 1.649)%, and (8.559 ± 1.697)% respectively], though it did not reach normal levels. No significant changes were observed in Treg cells, NK cells, and DCs after treatment.

Conclusions

This is the first study to systematically analyze immune status alterations following C5 complement inhibitor treatment in PNH patients, suggesting that the complement system may be involved in the development of immune escape mechanisms in PNH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemoglobinuria, ParoxysmalComplement C5Complement Inactivating AgentsHumansFemaleMaleAdultMiddle AgedRetrospective StudiesYoung AdultTreatment Outcome

Stichwörter der Autor:innen

B lymphocytesC5 complement inhibitorT lymphocytesimmune escapeparoxysmal nocturnal hemoglobinuria

Substanzen

Complement C5Complement Inactivating Agents

Autor:innen und Institutionen

  • Department of Hematology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
  • Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin, People's Republic of China.
  • Tianjin Institute of Hematology, Tianjin, People's Republic of China.

ORCID-Profile: Hui Liu, Mengting Che, Liyan Li, Yingying Chen, Zhaoyun Liu, Rong Fu

Förderung

  • National Natural Science Foundation of China
  • the Tianjin Municipal Natural Science Foundation
  • the Tianjin Science and Technology Planning Project
  • Tianjin Municipal Health Commission Project
  • Natural Science Foundation of Tianjin Municipality

Zitieren

APA

Liu, H., Che, M., Li, L., Wang, H., Wang, C., Wu, J., Chen, Y., Liu, Z., Li, L., & Fu, R. (2026). Analysis of the Recovery of Immune Status in the Patients With Paroxysmal Nocturnal Hemoglobinuria After Treatment With C5 Complement Inhibitor. Journal of Clinical Laboratory Analysis, 40(12). https://doi.org/10.1002/jcla.70211

Vancouver

Liu H, Che M, Li L, Wang H, Wang C, Wu J, et al. Analysis of the Recovery of Immune Status in the Patients With Paroxysmal Nocturnal Hemoglobinuria After Treatment With C5 Complement Inhibitor. Journal of Clinical Laboratory Analysis. 2026;40(12). doi:10.1002/jcla.70211

BibTeX
@article{Liu2026,
  author = {Liu, Hui and Che, Mengting and Li, Liyan and Wang, Honglei and Wang, Chaomeng and Wu, Junshu and Chen, Yingying and Liu, Zhaoyun and Li, Lijuan and Fu, Rong},
  title = {Analysis of the Recovery of Immune Status in the Patients With Paroxysmal Nocturnal Hemoglobinuria After Treatment With C5 Complement Inhibitor},
  journal = {Journal of Clinical Laboratory Analysis},
  year = {2026},
  volume = {40},
  number = {12},
  doi = {10.1002/jcla.70211}
}
Kostenlos starten →